The stock of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) increased by $13.94 on Friday to finish at $806.95, up 1.76 percent. The last five days have seen an average of 451,840 shares of common stock traded. 13 times new highs were reached in the current year, with a gain of $85.46. The average number of shares traded over the last 20 days was 615,205, while the average volume over the last 50 days totaled 651,586.
REGN stock appreciated 11.92% since last month. On 07/12/23, the company’s shares reached a one-month low of $714.15. The stock touched a high of $837.55 on 04/05/23, after rallying from a low of $572.22 in 52 weeks. The price of REGN stock has risen by 11.84% or $85.46 this year, reaching a new high 13 times. Still, the stock price is down -3.65% from the 52-week high.
Insider Transactions
REGN stock investors should be aware that Regeneron Pharmaceuticals Inc. (REGN) stock had its last reported insider trading activity 4 days ago on Aug 10. On Aug 10, Director Bassler Bonnie L sold 853 shares at $789.00 each. This transaction resulted in the insider making $673,017. On Aug 01, McCourt Marion sold 250 shares at a price of US$744.66. After the transaction, the insider now owns 20,053 shares. Director RYAN ARTHUR F had earlier sold 100 shares on Aug 01 for $736.59 a share. The transaction was completed for $73,659.
Valuation Metrics
Regeneron Pharmaceuticals Inc. (REGN) has a trailing price-to-earnings (P/E) ratio of 21.33. Beta for the stock is 0.19. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 6.79, the price-to-book (PB) ratio of 3.59, and the price-to-cash flow ratio of 28.65.
Financial Health
For the recent quarter, Regeneron Pharmaceuticals Inc.’s quick ratio was 4.60, while its current ratio was 5.50, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the recent quarter is 0.11, and the total debt to equity ratio is 0.11. As far as profitability goes, gross margin for the trailing twelve months is 86.40% percent. Regeneron Pharmaceuticals Inc.’s EBITDA margin for the recent year was 45.43%, whereas its operating margin stood at 34.20% for the same period. Based on annual data, it had gross profit of $10.61 billion and revenue of $12.17 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. REGN’s return on assets (ROA) during the last 12 months has been 14.60%. There was a 16.60% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 18.80%.
Earnings Surprise
A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $3.16 billion, while revenues rose by 9.53% to $3.16 billion. EBITDA was $1.12 billion for the quarter. At the end of Regeneron Pharmaceuticals Inc.’s most recent quarter, its liabilities totaled 6.64 billion, while its total debt was $2.7 billion. Equity owned by shareholders amounts to $108.56 million.
Technical Picture
Here’s a quick look at Regeneron Pharmaceuticals Inc.’s (REGN) price momentum from a technical perspective. As of 11 August, the RSI 9-day stood at 81.61%, suggesting the stock is Overbought, with a 26.43% historical volatility rate.
The stochastic %K and %D were 91.64% and 88.67% respectively, while the average true range (ATR) was 17.41. Based on the 14-day stochastic reading of 96.93%, the RSI (14) reading is 73.91%. On the 9-day MACD Oscillator, the stock is at 23.00, and the 14-day reading is at 34.96.
Analyst Ratings
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) was downgraded by Canaccord Genuity to a a Hold rating in its latest research report. The stock was previously rated as a a Buy. Analysts have assigned Regeneron Pharmaceuticals Inc. (REGN) an Overweight rating. REGN is a stock that is recommended for selling by 0 brokerage firms, while 9 companies recommend holding. The stock is underweighted by 1 analyst. Among the analysts who rate the stock, 3 rates it overweight and 14 others recommend it as a buy.
What is REGN’s price target for the next 12 months?
The current consensus forecast for the stock is between $650.00 and $1045.00, with a median target price of $885.00. In analyzing these forecasts, the average price target given by analysts for Regeneron Pharmaceuticals Inc. (REGN) is $876.05.
